TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for children aged 6 months to 5 years old


13 May 2022 - The TGA has received, and immediately commenced evaluation of, an application from Moderna to extend the use of its COVID-19 vaccine, Spikevax, to children aged 6 months to 5 years old.

Currently this mRNA vaccine is provisionally approved for immunisation to prevent COVID-19 in individuals aged 6 years and older (primary series of 2 doses administered at least 28 days apart) and as a booster dose for adults aged 18 years and older.

Read TGA News

Michael Wonder

Posted by:

Michael Wonder